Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
6 hedge funds and large institutions have $352K invested in Aoxing Pharmaceutical Company Inc. in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and 5 closing their positions.
81% more capital invested
Capital invested by funds: $195K → $352K (+$157K)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$188K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$81.3K |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$54.3K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$11.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$79K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$51K |
| 3 |
Goldman Sachs
New York
|
-$24K |
| 4 |
Renaissance Technologies
New York
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFA
1
BlackRock Fund Advisors
San Francisco,
California
| $185K | +$188K | +105,895 | New |
|
|
2
AQR Capital Management
Greenwich,
Connecticut
| $80K | +$81.3K | +45,700 | New |
|
|
RCM
3
Rotella Capital Management
Bellevue,
Washington
| $53K | +$54.3K | +30,499 | New |
|
|
EWM
4
Evercore Wealth Management
New York
| $23K | – | – | – |
|
|
BIM
5
BlackRock Investment Management
Wilmington,
Delaware
| $11K | +$11.2K | +6,274 | New |
|
|
VKH
6
Virtu KCG Holdings
New York
| – | -$79K | -46,541 | Closed |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$51K | -30,465 | Closed |
|
|
8
Goldman Sachs
New York
| – | -$24K | -14,321 | Closed |
|
|
9
Renaissance Technologies
New York
| – | -$19K | -11,300 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | +$14 | +8 | New |
|
AXN Hedge Fund Activity: Q2 2015 in Review
6 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q2 2015, worth a combined $352K — up 81% from $195K a quarter earlier.
Fund positioning in AXN was balanced in Q2 2015: 5 funds opened new positions, 5 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $188K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $79K sold.
- 6 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $352K of Aoxing Pharmaceutical Company Inc. stock for Q2 2015, up 81% quarter-over-quarter.
- 5 funds opened new Aoxing Pharmaceutical Company Inc. positions in Q2 2015 and 5 closed out, a net change of 0 holders.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $188K added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q2 2015 was Virtu KCG Holdings, an estimated $79K sold.
Based on aggregated 13F filings for Q2 2015.